Peru: First group of COVID-19 clinical trial candidates completed

Photo: EFE

15:11 | Lima, Aug. 31.

The first group of 3,000 candidates for COVID-19 clinical trials in Peru has been completed. They will participate —as volunteers— in Phase 3 clinical trials of the inactivated vaccines developed by Chinese laboratory Sinopharm.

In a statement, the team of researchers from Cayetano Heredia and San Marcos Universities thanked the trust, acceptance and enthusiasm shown during the first volunteer registration for Phase 3 clinical trials of two inactivated vaccines against COVID-19 in Peru.

"We were able to achieve the goal of registering 3,000 candidates in about 10 minutes. This encourages us to continue working and to make this study exemplary, so that it can raise the name of Peru in terms of scientific research," the statement reads.

According to the research team, this goal was achieved thanks to citizens' commitment to the necessary development of a COVID-19 vaccine in order to prevent the effects of the pandemic.

The online registration of the second group (of another 3,000 candidates) going to the San Marcos' Clinical Trials Unit will open in the coming days, as soon as the corresponding registration and approval stages are completed.

According to Foreign Affairs Minister Mario Lopez, Peru could have a COVID-19 vaccine by the beginning of next year, as a result of the negotiations conducted at the bilateral and multilateral levels so as to achieve that goal.

(END) LIT/RMB/MVB

Published: 8/31/2020

Video más visto

Peru: First group of COVID-19 clinical trial candidates completed

Most read